The defective manufacturing and supply has been traced to a private firm in Karachi, which marketed the injection within the city of Karachi.
DRAP issues rapid alert on falsified drugs. The Drug Regulatory Authority of Pakistan (DRAP) has made a proactive response to the illegal drugs and medical devices issues, directing the provincial governments to control the activities of the sale, use, and importation of unregistered medical products.
This is in the wake of the illegal redemptive prescription drugs and surgical equipment being used in hospitals, which was a threat to the public.
Sources further stated that letters have been dispatched by DRAP to all four provinces, including Azad Kashmir and Gilgit-Baltistan, and urged them to take measures against offenders of the illicit trade.
The regulatory body has also instructed its field force to perform intensive policing on the medical market and research the network of illegal goods.
In another case, DRAP has also announced the prohibition of sales and use of the Familia injection a contraceptive that was recently found to have a defective batch.
The defective manufacturing and supply has been traced to a private firm in Karachi, which marketed the injection within the city of Karachi, Pakistan.
This announcement followed the news that the particular batch of Familia injection had been declared for recall after the Central Drug Testing Laboratory found it to be below the required standards, coupled with the suspension of its distribution by DRAP alerting about safety and health risks of potential blood contamination.
It is appreciated that DRAP is trying to control the business of manufacture and distribution of drugs and protect the people. It is because of actions like these that this authority can keep the people safe from the adverse effects of illicit and poor-quality medical supplies.
